Boston Scientific Corp. vs Johnson & Johnson
BSX vs JNJ — side-by-side comparison from reported financials. BSX leads 4, JNJ leads 6 of 10 comparable metrics.
Boston Scientific Corp.
BSX · Healthcare
$42.62+1.37%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | BSX | JNJ |
|---|---|---|
| Price | $42.62 | $261.79 |
| Market cap | $61.8B | $631B |
| Revenue (TTM) | $21.0B | $97.9B |
| Revenue growth | +16.5% | +5.6% |
| Net margin | 17.5% | 21.5% |
| Free cash flow | $3.63B | $22.2B |
| Net cash (debt) | ($9.47B) | ($27.8B) |
| 1-year price return | -56.2% | +37.0% |
| P/E | 16.9 | 29.9 |
| P/E vs own history (cheap-side %) | 99% | 16% |
| Dividend yield | 0.00% | 2.00% |
| Return on equity | 15% | 26% |
| Altman Z-score | 2.58 | — |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 59,000 | 140,800 |
Full résumé-style profiles: BSX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.